NCT05978050 - Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma | Biotech Hunter

Enrollment

354

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2026

Conditions

Gastric or Esophagogastric Junction Adenocarcinoma

Interventions

DRUG

nimotuzumab plus paclitaxel

Nimotuzumab injection: 50mg/10ml/stick Paclitaxel: 30mg/5ml/stick

DRUG

placebo plus paclitaxel

placebo: 50mg/10ml/stick Paclitaxel: 30mg/5ml/stick

Trial Locations (1)

RECRUITING

National Sun Yat-sen University Cancer Center, Guangzhou